Luigi Marzio Biasucci

Luigi Marzio Biasucci

Auto-generated profile, based on publicly available information

Luigi Marzio Biasucci

Institute of Cardiology, Catholic University, Rome, Italy

Research Focus & Metrics

Academic Career Length

42Years (1985-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 August 1994 in New England Journal of Medicine
Verified
Journal Article
Open access
PDF file
GLGiovanna Liuzzo
Giovanna Liuzzo
LBLuigi M. Biasucci
Luigi M. Biasucci
JGJ. Ruth Gallimore
J. Ruth Gallimore
RGRita L. Grillo
Rita L. Grillo
ARAntonio G. Rebuzzi
Antonio G. Rebuzzi
AMAttilio Maseri
Attilio Maseri
The pathogenesis of unstable angina is poorly understood, and predicting the prognosis is problematic. Evidence suggests that there may be active inflammation, possibly in the coronary arteries, in this syndrome. We therefore studied the prognostic value of measurements of the circulating acute-phase reactants C-reactive protein and serum amyloid A protein, which are sensitive indicators of inflammation.

4 July 2002 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
ABAntonino Buffon
Antonino Buffon
LBLuigi M. Biasucci
Luigi M. Biasucci
GLGiovanna Liuzzo
Giovanna Liuzzo
GDGiuseppe D'Onofrio
Giuseppe D'Onofrio
FCFilippo Crea
Filippo Crea
AMAttilio Maseri
Attilio Maseri
Inflammation within vulnerable coronary plaques may cause unstable angina by promoting rupture and erosion. In unstable angina, activated leukocytes may be found in peripheral and coronary-sinus blood, but it is unclear whether they are selectively activated in the vascular bed of the culprit stenosis.

21 June 2012 in European Heart Journal
Verified
Journal Article
Open access
PDF file
KTKristian Thygesen
Kristian Thygesen
JMJohannes Mair
Johannes Mair
EGEvangelos Giannitsis
Evangelos Giannitsis
CMChristian Mueller
Christian Mueller
BLBertil Lindahl
Bertil Lindahl
TCthe Study Group on Biomarkers in Cardiology of the ESC Working Group on Acute Cardiac Care
the Study Group on Biomarkers in Cardiology of the ESC Working Group on Acute Cardiac Care
Recommendations for the use of cardiac troponin (cTn) measurement in acute cardiac care have recently been published.1 Subsequently, a high-sensitivity (hs) cTn T assay was introduced into routine clinical practice.2 This assay, as others, called highly sensitive, permits measurement of cTn concentrations in significant numbers of apparently illness-free individuals. These assays can measure cTn in the single digit range of nanograms per litre (=picograms per millilitre) and some research assays even allow detection of concentrations <1 ng/L.2–4 Thus, they provide a more precise calculation of the 99th percentile of cTn concentration in reference subjects (the recommended upper reference limit [URL]). These assays measure the URL with a coefficient of variation (CV) 10% at the 99th percentile URL limiting that ability.5–7 However, the less precise cTn assays do not cause clinically relevant false-positive diagnosis of acute myocardial infarction (AMI) and a CV <20% at the 99th percentile URL is still considered acceptable.8

3 August 2010 in European Heart Journal
Verified
Journal Article
Open access
PDF file
KTKristian Thygesen
Kristian Thygesen
JMJohannes Mair
Johannes Mair
HKHugo Katus
Hugo Katus
MPMario Plebani
Mario Plebani
PVPer Venge
Per Venge
TCthe Study Group on Biomarkers in Cardiology of the ESC Working Group on Acute Cardiac Care
the Study Group on Biomarkers in Cardiology of the ESC Working Group on Acute Cardiac Care
The release of cardiomyocyte components, i.e. biomarkers, into the bloodstream in higher than usual quantities indicates an ongoing pathological process. Thus, detection of elevated concentrations of cardiac biomarkers in blood is a sign of cardiac injury which could be due to supply–demand imbalance, toxic effects, or haemodynamic stress. It is up to the clinician to determine the most probable aetiology, the proper therapeutic measures, and the subsequent risk implied by the process. For this reason, the measurement of biomarkers always must be applied in relation to the clinical context and never in isolation. There are a large number of cardiac biomarkers, but they can be subdivided into four broad categories, those related to necrosis, inflammation, haemodynamic stress, and/or thrombosis. Their usefulness is dependent on the accuracy and reproducibility of the measurements, the discriminatory limits separating pathology from physiology, and their sensitivity and specificity for specific organ damage and/or disease processes. In recent years, cardiac biomarkers have become important adjuncts to the delivery of acute cardiac care. Therefore, the Working Group on Acute Cardiac Care of the European Society of Cardiology established a committee to deal with ongoing and newly developing issues related to cardiac biomarkers. The intention of the group is to outline the principles for the application of various biomarkers by clinicians in the setting of acute cardiac care in a series of expert consensus documents. The first of these will focus on cardiac troponin, a pivotal marker of cardiac injury/necrosis.

1 September 1996 in Circulation
Verified
Journal Article
Closed access
PDF file
LBLuigi M. Biasucci
Luigi M. Biasucci
AVAlessandra Vitelli
Alessandra Vitelli
GLGiovanna Liuzzo
Giovanna Liuzzo
SASergio Altamura
Sergio Altamura
GCGiuseppina Caligiuri
Giuseppina Caligiuri
AMAttilio Maseri
Attilio Maseri
Background Elevated plasma levels of C-reactive protein have been found in the majority of patients with unstable angina. The evidence of elevated levels of acute-phase proteins in unstable angina is in line with a growing body of evidence that suggests that inflammation plays a role in this syndrome and is an indirect sign of increased production of interleukin-6, which is the major determinant of acute-phase–protein production by the liver. However, in unstable angina, there is no direct proof of the role played by interleukin-6. Methods and Results We measured levels of interleukin-6 in 38 patients with unstable angina at the time of their admission to the coronary care unit and in 29 patients with stable angina. In the same groups of patients, we also measured C-reactive protein. Interleukin-6 (undetectable, ie, <3 pg/mL, in healthy volunteers) was detectable in 23 (61%) of 38 patients with unstable angina but in only 6 (21%) of 29 with stable angina ( P <.01). Median interleukin-6 levels were 5.25 pg/mL (range, 0 to 90 pg/mL) in patients with unstable angina but were below the detection limit of the assay in patients with stable angina (range, 0 to 7 pg/mL). A significant correlation was observed between interleukin-6 and C-reactive protein levels ( r =.4, P =.013). Conclusions Our study demonstrates that raised levels of interleukin-6 are common in unstable angina, correlate with C-reactive protein, and are associated with prognosis, thus confirming the importance of the cytokine pathway for the production by the liver of acute-phase proteins and strengthening the importance of inflammation in this syndrome. Further studies are required to elucidate better the role of interleukins in unstable angina.

23 February 1999 in Circulation
Verified
Journal Article
Closed access
PDF file
LBLuigi M. Biasucci
Luigi M. Biasucci
GLGiovanna Liuzzo
Giovanna Liuzzo
RGRita L. Grillo
Rita L. Grillo
GCGiuseppina Caligiuri
Giuseppina Caligiuri
ARAntonio G. Rebuzzi
Antonio G. Rebuzzi
AMAttilio Maseri
Attilio Maseri
Background —In a group of patients admitted for unstable angina, we investigated whether C-reactive protein (CRP) plasma levels remain elevated at discharge and whether persistent elevation is associated with recurrence of instability. Methods and Results —We measured plasma levels of CRP, serum amyloid A protein (SAA), fibrinogen, total cholesterol, and Helicobacter pylori and Chlamydia pneumoniae antibody titers in 53 patients admitted to our coronary care unit for Braunwald class IIIB unstable angina. Blood samples were taken on admission, at discharge, and after 3 months. Patients were followed for 1 year. At discharge, CRP was elevated (>3 mg/L) in 49% of patients; of these, 42% had elevated levels on admission and at 3 months. Only 15% of patients with discharge levels of CRP <3 mg/L but 69% of those with elevated CRP ( P <0.001) were readmitted because of recurrence of instability or new myocardial infarction. New phases of instability occurred in 13% of patients in the lower tertile of CRP (≤2.5 mg/L), in 42% of those in the intermediate tertile (2.6 to 8.6 mg/L), and in 67% of those in the upper tertile (≥8.7 mg/L, P <0.001). The prognostic value of SAA was similar to that of CRP; that of fibrinogen was not significant. Chlamydia pneumoniae but not Helicobacter pylori antibody titers significantly correlated with CRP plasma levels. Conclusions —In unstable angina, CRP may remain elevated for at ≥3 months after the waning of symptoms and is associated with recurrent instability. Elevation of acute-phase reactants in unstable angina could represent a hallmark of subclinical persistent instability or of susceptibility to recurrent instability and, at least in some patients, could be related to chronic Chlamydia pneumoniae infection.